Clinical Trials

Mesothelioma

NCT06097728 2026-04-02

eVOLVE-Meso

Phase 3 Recruiting

825 enrolled

Mesothelioma, Malignant, Mesothelioma

NCT05136677 2026-01-23

CheckMate 6DW

Phase 2 Completed

102 enrolled

Mesothelioma, Malignant

NCT05584670 2026-01-20

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

542 enrolled

385 enrolled 17 charts 4 FDA

Solid Tumor

NCT02060188 2025-11-06

CheckMate142

Phase 2 Completed

GastrointestinalOther solid neoplasm

Microsatellite Unstable Colorectal Cancer

NCT03195478 2025-09-15

A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors

37 enrolled 32 charts

Phase 1/2 Active not recruiting

Solid Tumor

NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

57 enrolled

GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT03126110 2025-08-14

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

145 enrolled 47 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02913313 2025-04-20

A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

101 enrolled 34 charts

Broad Solid Tumor

NCT01928394 2024-12-27

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

1,163 enrolled 33 charts 2 FDA

Advanced or Metastatic Solid Tumors

NCT03523819 2024-09-19

A Study of CS1002 in Subjects with Advanced Solid Tumors

Phase 1 Completed

91 enrolled

Solid Tumor, Adult

NCT06514651 2024-07-23

MAQ-001 in Patients With Advanced Solid Tumors

Phase 1 Recruiting

30 enrolled

605 enrolled 17 charts 3 FDA

Advanced Solid Tumor

NCT02899299 2024-05-21

CheckMate743

Phase 3 Completed

Mesothelioma

NCT05284214 2023-09-15

SALIENT

Phase 2 Withdrawn

Solid Tumor

NCT03241173 2022-09-27

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

52 enrolled 25 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03865082 2022-02-17

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

Phase 2 Active not recruiting

30 enrolled